Cargando…
SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review
INTRODUCTION: The obesity epidemic is closely linked to the rising prevalence of type 2 diabetes (T2D). Body weight reduction remains an important challenge in patients with T2D, as it requires changing their overall metabolic control. Of all glucose-lowering therapies, only sodium–glucose cotranspo...
Autores principales: | Janež, Andrej, Fioretto, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342745/ https://www.ncbi.nlm.nih.gov/pubmed/34244976 http://dx.doi.org/10.1007/s13300-021-01104-z |
Ejemplares similares
-
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015) -
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
por: Thomas, Merlin C, et al.
Publicado: (2023) -
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018) -
SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM)
por: Sohail, Erum, et al.
Publicado: (2021) -
Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)